Link To Better Image

Transcripts

MS. GIRAND:
      Our next speaker is Dr. Phil Tarr. I first encountered Dr. Tarr on the internet, not in a chat room, but actually reviewing transcripts of juice meetings in Washington DC, where he was asked to describe the disease and what happened at these particular meetings.
      I then, being the kind of person all of you now know me to be, followed up by calling him on the phone thinking it was a very long shot that anybody was going to ever call me back. I was completely stunned to find that he did call me back.
      And I had a strong feeling when we called him and asked him to speak at this conference that he would show his usual self and be very amenable. So I would like to ask that you help me in welcoming Dr. Phillip Tarr.

DR. TARR:
      Thank you very much.
      I would first like to thank the whole group here in their efforts for preventing this terrible infection altogether.
      We're all here to talk about long-term consequences of HUS. But the best way to prevent the long-term consequences is to prevent the initial infection in the first place. And whatever you can do to support efforts to reduce this agent in the environment, I applaud that.
      This talk is going to be confined to Hemolytic Uremic Syndrome, the form of vascular and kidney injury that follows infections with one or more Shiga toxin producing E. coli, of which E. coli 0157 is the most commonly recognized, and probably the most commonly occurring variety in North America, Europe and Northern Asia. In other countries there's a slightly different etiology.
      This is the infection I'm going to focus on and the consequences of this infection are what I will discuss.

Slide 1 of 27 | Next